Announcement PDF ASX Announcement Chair and Deputy Chair Appointments Melbourne, Australia; 1 October 2026: On behalf of the Board of Directors, Starpharma (ASX: SPL, US OTC: SPHRY) today announces that, as previously foreshadowed, Mr Rob Thomas AO will retire as Chair of the Board at the conclusion of the 2026 Annual General Meeting (AGM) in November, following 12 years of distinguished service as Chair. Current non-executive directors Dr Russell Basser and Mr David McIntyre will assume the roles of Chair and Deputy Chair, respectively, from the close of the AGM. The Board has also requested that Mr Thomas continue as a non-executive director, subject to shareholder approval, to support continuity and an orderly Chair transition. These changes reflect Starpharma’s increasing focus on targeted oncology therapies and broader international engagement.The Board believesthis leadershipstructure is well suited to theCompany’s next phase, bringing together Dr Basser’s deep clinical oncology and global drug development expertise with Mr McIntyre’s strong US commercial, business development and capital markets experience. Strategic rationale This transition is intended to ensure the Board’s leadership remains closely aligned with Starpharma’s next phase of development. As the Company sharpens its focus on targeted oncology therapies and advances its international activities, the Board considers it important that its leadership structure reflects the capabilities most relevant to clinical development, commercialisation, partnering and capital markets engagement. The appointments of Dr Basser as Chair and Mr McIntyre as Deputy Chair will strengthen Board oversight in these areas, while Mr Thomas’ continued service as a non-executive director, subject to shareholder approval, will support continuity and an orderly transition. Mr Rob Thomas AO, Starpharma’s Chairman, said: “It has been a privilege to serve as Chair during a formative period for Starpharma in advancing its dendrimer technology. This company has a very exciting future under our CEO Cheryl Maley. It is important to align board responsibilities in a way that supports Cheryl and complements our future strategy as the company sharpens its focus on targeted oncology therapies. As current non-executive directors, Russell and David already know the business and are well placed to step into these roles at an important point in Starpharma’s journey. Russell brings deep clinical oncology and international drug development expertise, built over more than 30 years across medicine and biopharmaceutical development, while David brings substantial global life sciences, commercial and US capital markets experience.” Background on Dr Russell Basser Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles while at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL’s Clinical Research and Development group, and for the conception and execution of CSL’s clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus’ executive leadership team in 2015 and served as SVP of Research and Development until his retirement in April 2022. 2 Dr Basser holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) and a Doctor of Medicine (MD) from the University of Melbourne. He is a Fellow of The Royal Australasian College of Physicians and an author of more than 90 peer-reviewed papers, reviews, and book chapters. Dr Basser has previously served on the Board of the ANZ Breast Cancer Trials Group and advised on its Scientific Advisory Board; and the Breast, Bowel and Lung Cancer Advisory Committees of the Anti- Cancer Council of Victoria. Dr Basser has extensive experience in the medical and biopharmaceutical industry, with expert knowledge of R&D, drug and vaccine development, clinical and regulatory affairs, business development, strategy and risk management, and commercialisation. Background on David McIntyre Mr McIntyre has more than 20 years of executive experience in the life sciences sector, having held various C-suite level roles at Anthos Therapeutics, Inc., Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., Heartware® International, Inc., and Braeburn, Inc. Mr McIntyre’s experience also includes seven years as a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital and growth equity fund, giving him a deep knowledge of, and extensive contacts in, the US pharmaceutical, medical device and biotech markets. During this time, Mr McIntyre served as a non-executive director of several US life science companies. Prior to entering life sciences, Mr McIntyre practised as a senior attorney at Baker & McKenzie and KPMG, specialising in M&A, initial public offerings, and corporate law, and also held senior finance roles in both multinational companies and small growth companies. Mr McIntyre is based in the US and brings an international lens to life science licensing and commercialisation, marketing and business development, and M&A/capital markets. Mr McIntyre has significant experience in the areas of accounting, corporate finance, audit, risk management, organisational strategy, drug development, regulatory and corporate affairs. Mr McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, Australia, a Bachelor of Laws from the University of Technology, Sydney, and a Master of Business Administration from Duke University Fuqua School of Business (Fuqua Scholar) in Durham, North Carolina, in the US. Mr McIntyre is a Certified Practising Accountant and is also admitted as a legal practitioner of the Supreme Court of New South Wales and of the High Court of Australia. Mr McIntyre is Starpharma’s nominated director on the Board of Petalion Therapeutics Limited, which is an associated entity of Starpharma. He is presently the Chief Financial Officer of clinical-stage pharmaceutical company Inhibikase Therapeutics Inc (NASDAQ: IKT). About Starpharma Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimersare precise,synthetically manufactured,nanoscalemolecules.Their unique properties—including their size,structure,high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. 3 Investor & Media Relations Gabriella Hold gaby@thecapitalnetwork.com.au Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, Chief Financial and Operations Officer and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford VIC 3067 Disclosure This ASX Announcement was authorised for release by the Board of Directors. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.